NorthWest Biotherapeutics Inc (NWBO)

[Lykiri]

GermanCol,

you said:

Of the 22 initially unknown but then identified, my best guess of how they were distributed in the beginning would be 16 in the nGBM arm.

16 in the nGBM arm. Sounds reasonable. (my guess is 15)
Do we know the MGMT gene promoter of the 16 identified DCVax-L patients?
Well, let's go back to the JA:

The MGMT gene promoter was methylated in 39.6% of patients (n=131) and unmethylated in 48.9% (n=162), with information not available for 11.5% (n=38; the missing data relates to the early patients enrolled a decade ago)

The MGMT gene promoter was methylated in 39.6% of patients ( n= 131)
331 patients in the trial. 232 DCVax-L/99 placebo. 232/331= 70%
70% of 131 MGMT methylated patients = about 91 MGMT metylated DCVax-L patients.
NYAS data: 90 MGMT metylated DCVax-L patients.

In my opinion, the number of MGMT methylated DCVax-L patients has not changed between 2017 and 2022. (90 MGMT methylated DCVax-L patients in 2017 and 90 MGMT methylated DCVax-L patients in 2022)
IMO, the 16 (or 15 in my opinion) initially unknown DCVax-L patients are all MGMT unmethylated.

My question: why do you think the majority of the 35 non-crossover placebo patients are MGMT methylated?